Acute myeloid leukemia

Caribou Biosciences Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Tuesday, August 8, 2023
Exercise, Rachel Haurwitz, Maintenance, CRISPR, Doctor of Philosophy, Acute myeloid leukemia, AML, Patent, Patient, MM, CR, Research, FDA, IND, ORR, Pharmaceutical industry, Security (finance), Fine chemical, Vaccine, Bookkeeping, Reindeer, Pfizer

-- Closed upsized public offering including full exercise of underwriters’ option to purchase additional shares, delivering $134.6 million in net proceeds --

Key Points: 
  • As of the June 20, 2023 data cutoff date, results demonstrated:
    CB-010 was generally well tolerated with adverse events consistent with autologous and allogeneic anti-CD19 CAR-T cell therapies.
  • $25.0 million Pfizer investment: On June 30, 2023, Pfizer invested $25.0 million in Caribou common shares.
  • This amount does not include the approximately $134.6 million in net proceeds from the Company’s underwritten public offering completed in the third quarter of 2023.
  • Net loss: Caribou reported a net loss of $29.5 million for the three months ended June 30, 2023, compared to $26.7 million for the same period in 2022.

Prime Medicine Reports Second Quarter 2023 Financial Results and Provides Business Updates

Retrieved on: 
Monday, August 7, 2023
Myelodysplastic syndrome, Exercise, Chronic granulomatous disease, Partnership, Gene, SCIP, Eye, Immunotherapy, G&A, Toxicity, Research, Economics, CD34, Acute myeloid leukemia, Transplant, MDS, Health, AML, Investment, Patient, Cancer, Annual general meeting, Cell, CGD, American Society of Gene and Cell Therapy, Liver, Prime editing, HSC, R, Therapy, CD117, Society, DSM-IV codes, D, Medical device, Pharmaceutical industry, Vaccine, Video game, Cryptocurrency, IND

CAMBRIDGE, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today reported financial results and provided business updates for the second quarter ended June 30, 2023.

Key Points: 
  • In May 2023, Prime Medicine presented new preclinical data at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting.
  • Prime Medicine expects the following activities and next steps to drive the Prime Editing platform forward:
    Initiate investigational new drug (IND)-enabling studies for PM359 in CGD in 2023.
  • Maximize Prime Editing’s broad therapeutic potential and create value through strategic business development that extends the reach and impact of Prime Editing to areas beyond Prime Medicine’s current areas of focus.
  • Second Quarter 2023 Financial Results:
    R&D Expenses: Research and development (R&D) expenses were $34.6 million for the three months ended June 30, 2023, as compared to $18.9 million for the three months ended June 30, 2022.

XNK Therapeutics to present two abstracts at the Society for Immunotherapy of Cancer's meeting in San Diego in November

Retrieved on: 
Monday, August 7, 2023
Abstract, Society, CSO, Cancer, SITC, Immunotherapy, Bladder cancer, NK, Research, Acute myeloid leukemia, MD Anderson Cancer Center, AML, Patient, University, Karolinska Institute, Therapy, Environment, Pharmaceutical industry

HUDDINGE, Sweden, Aug. 7, 2023 /PRNewswire/ -- XNK Therapeutics will participate at the SITC meeting in San Diego in November and present the latest research from the company's leading preclinical projects in bladder cancer and acute myeloid leukemia (AML). Two abstracts have been accepted for presentation at the meeting:

Key Points: 
  • XNK Therapeutics AB today announced that the abstracts Harnessing the potential of autologous NK cells for immunotherapy of patients with advanced bladder cancer and Feeder-Free Expansion of Autologous Cytotoxic NK Cells for Acute Myeloid Leukemia Treatment will be presented at the 38th Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego in November.
  • HUDDINGE, Sweden, Aug. 7, 2023 /PRNewswire/ -- XNK Therapeutics will participate at the SITC meeting in San Diego in November and present the latest research from the company's leading preclinical projects in bladder cancer and acute myeloid leukemia (AML).
  • The yearly SITC meeting is a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy.
  • It consists of cutting-edge research presentations by experts in the field.

XNK Therapeutics to present two abstracts at the Society for Immunotherapy of Cancer's meeting in San Diego in November

Retrieved on: 
Monday, August 7, 2023
Abstract, Society, CSO, Cancer, SITC, Immunotherapy, Bladder cancer, NK, Research, Acute myeloid leukemia, MD Anderson Cancer Center, AML, Patient, University, Karolinska Institute, Therapy, Environment, Pharmaceutical industry

HUDDINGE, Sweden, Aug. 7, 2023 /PRNewswire/ -- XNK Therapeutics will participate at the SITC meeting in San Diego in November and present the latest research from the company's leading preclinical projects in bladder cancer and acute myeloid leukemia (AML). Two abstracts have been accepted for presentation at the meeting:

Key Points: 
  • XNK Therapeutics AB today announced that the abstracts Harnessing the potential of autologous NK cells for immunotherapy of patients with advanced bladder cancer and Feeder-Free Expansion of Autologous Cytotoxic NK Cells for Acute Myeloid Leukemia Treatment will be presented at the 38th Meeting of the Society for Immunotherapy of Cancer (SITC) in San Diego in November.
  • HUDDINGE, Sweden, Aug. 7, 2023 /PRNewswire/ -- XNK Therapeutics will participate at the SITC meeting in San Diego in November and present the latest research from the company's leading preclinical projects in bladder cancer and acute myeloid leukemia (AML).
  • The yearly SITC meeting is a multidisciplinary educational and interactive environment focused on improving outcomes for cancer patients by incorporating strategies based on basic and applied cancer immunotherapy.
  • It consists of cutting-edge research presentations by experts in the field.

IGM Biosciences Announces Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
CD38, Hepatotoxicity, Lupus, Bevacizumab, RA, CRC, Investment, Progression-free survival, IGM, CD20, FOLFIRI, DR5, Clinical trial, Immunoglobulin M, G&A, GAAP, SLE, PFS, Acute myeloid leukemia, Net, Patient, Administration, Colorectal cancer, Liver, Research and development, R, Research, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Safety, IND, Food, Rheumatoid arthritis, Pharmaceutical industry, Medical imaging, Sanofi

MOUNTAIN VIEW, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended June 30, 2023.

Key Points: 
  • MOUNTAIN VIEW, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced its financial results for the quarter ended June 30, 2023.
  • Collaboration Revenue: For the second quarter of 2023, collaboration revenues were $0.4 million, compared to $0.4 million for the same period in 2022.
  • Research and Development (R&D) Expenses: For the second quarter of 2023, R&D expenses were $55.7 million, compared to $47.2 million for the same period in 2022.
  • General and Administrative (G&A) Expenses: For the second quarter of 2023, G&A expenses were $13.0 million, compared to $12.4 million for the same period in 2022.

Kura Oncology Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
European Hematology Association, Head, CRH, Cancer, Kura, ID, Acute myeloid leukemia, PI3K, Congress, AML, Investigational New Drug, Investment, Patient, KURA, EHA, HNSCC, CR, FLT3, Webcast, Toxic leukoencephalopathy, Research, FDA, Health, Safety, FTI, Disease, Pharmaceutical industry, Video game, Cryptocurrency

ET –

Key Points: 
  • ET –
    SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2023 financial results and provided a corporate update.
  • Research and development expenses for the second quarter of 2023 were $28.2 million, compared to $24.3 million for the second quarter of 2022.
  • General and administrative expenses for the second quarter of 2023 were $11.8 million, compared to $11.1 million for the second quarter of 2022.
  • ET / 1:30 p.m. PT today, August 3, 2023, to discuss the financial results for the second quarter 2023 and to provide a corporate update.

Schrödinger Reports Second Quarter 2023 Financial Results

Retrieved on: 
Wednesday, August 2, 2023
Health, Technology, Software, General Health, Pharmaceutical, Biotechnology, Myelodysplastic syndrome, Gastrointestinal disease, CDC7, Type 2 diabetes, Obesity, Table, Lymphoid leukemia, Ligand, Pharmacokinetics, GAAP, ID, Ulcerative colitis, Psoriasis, Acute myeloid leukemia, MALT1, Patient, Investment, TYK2, Drug discovery, FDA, Therapy, IND, Safety, Pharmaceutical industry, Video game, Bank

Operating expense growth in 2023 is expected to be significantly lower than operating expense growth in 2022.

Key Points: 
  • Operating expense growth in 2023 is expected to be significantly lower than operating expense growth in 2022.
  • Cash used for operating activities in 2023 is expected to be below cash used for operating activities in 2022.
  • For the third quarter of 2023, software revenue is expected to range from $27 million to $31 million.
  • Schrödinger will host a conference call to discuss its second quarter 2023 financial results on Wednesday, August 2, 2023, at 4:30 p.m.

Faron to Participate in Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference

Retrieved on: 
Wednesday, August 2, 2023
Canaccord Genuity, Faron Pharmaceuticals, AIM, HMA, SOC, Immunotherapy, Acute myeloid leukemia, MDS, Nasdaq First North, AML, Standard of care, Patient, Syndrome, Cancer, FDA, BLA, Conference, Pharmaceutical industry, Online shopping

The updated BEXMAB data support advancement to Phase II in H2 2023 focusing on SoC relapsed/refractory AML and MDS patients failing hypomethylating agents (HMA).

Key Points: 
  • The updated BEXMAB data support advancement to Phase II in H2 2023 focusing on SoC relapsed/refractory AML and MDS patients failing hypomethylating agents (HMA).
  • The Company’s filing of its first Biologics License Application (BLA) to the FDA is planned for H1 2025.
  • A live webcast of the fireside chat can be found here and in the Investor Relations section of Faron’s website at https://www.faron.com/investors/results-presentations .
  • Following the completion of the event, a webcast replay of the fireside chat will be available on the website for 90 days.

Bio-Path Holdings Announces Positive Results from Interim Analysis of Phase 2 Clinical Trial of Prexigebersen in Acute Myeloid Leukemia

Retrieved on: 
Tuesday, August 1, 2023
Holding, ELN, Cohort, Food, Aes, Food and Drug Administration, Stage 2, Acute myeloid leukemia, AML, Patient, Clutch (eggs), RNA interference, FDA, Venetoclax, Disease, Pharmaceutical industry, Medical imaging, Decitabine

HOUSTON, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today reports interim data from Stage 2 of the Company’s Phase 2 study of prexigebersen in combination with decitabine and venetoclax for the treatment of acute myeloid leukemia (AML). Prexigebersen continues to be well-tolerated and has now shown compelling efficacy results in two reporting cohorts including evaluable newly diagnosed AML patients and evaluable refractory/relapsed AML patients, which exceed outcomes with frontline therapy. The protocol for the Phase 2 study allows Bio-Path to conduct an interim efficacy analysis on each cohort at its discretion. Additional data will become available as final efficacy reviews are conducted.

Key Points: 
  • The protocol for the Phase 2 study allows Bio-Path to conduct an interim efficacy analysis on each cohort at its discretion.
  • Fourteen newly diagnosed patients were evaluable in Cohort 1 and treated with at least one cycle of the prexigebersen, decitabine and venetoclax combination therapy.
  • All patients in this cohort (median age 75) were adverse risk by 2017 European Leukemia Net (ELN) guidelines (n=10) or secondary AML (n=4).
  • Prexigebersen was well-tolerated, and adverse events (AEs) were generally consistent with decitabine and venetoclax treatment and/or for AML.

ImmunoGen Reports Recent Progress and Second Quarter 2023 Financial Results

Retrieved on: 
Monday, July 31, 2023
Health, General Health, Capital expenditure, ASH, Marketing, MOH, European Medicines Agency, Survival, American Society of Clinical Oncology, György Enyedi (geographer), ESGO, Congress, Huadong Medicine, Patient, National Medical Products Administration, Spacecraft, European Hematology Association, Research, University Clinical Centre in Gdańsk, Mirvetuximab soravtansine, EMA, ADC, FDA, NMPA, Cancer, NSCLC, Acute myeloid leukemia, PROC, Ministry, PIN, ImmunoGen, MAA, Ovarian cancer, ORR, European Society of Gynaecological Oncology, Clinical trial, ASCO, AML, Azacitidine, Annual general meeting, EHA, BPDCN, Society, Food, Medicine, Vaccine, Pharmaceutical industry, Mobile phone

(Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2023.

Key Points: 
  • (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2023.
  • Research and development expenses were $50.1 million for the quarter ended June 30, 2023 compared to $51.4 million for the quarter ended June 30, 2022.
  • Selling, general and administrative expenses were $36.4 million for the quarter ended June 30, 2023 compared to $23.8 million for the quarter ended June 30, 2022.
  • Net loss for the second quarter of 2023 was $4.2 million, or $0.02 per share, compared to a net loss of $62.0 million, or $0.24 per share, for the second quarter of 2022.